Table 2

Relative risks of recurrent disease and death from melanoma according to MCM3 expression
Risk of disease recurrence Risk of death from melanoma
Univariable Multivariable Univariable Multivariable
n (events) HR (95%CI) HR (95%CI) n (events) HR (95%CI) HR (95%CI)
Age
Continuous 255 (47) 1.01 (0.97-1.05) 255 (28) 1.05 (0.99-1.10) 1.08 (1.02-1.14)
Gender
Female 132 (21) 1,00 132 (9) 1,00
Male 123 (26) 1.51 (0.85-2.70) 123 (19) 2.77 (1.25-6.14)
Clark level
II 93 (5) 1,00 93 (2) 1,00
III 103 (21) 4.39 (1.65-11.65) 103 (14) 7.16 (1.63-31.50)
IV-V 51 (21) 9.99 (3.76-26.55) 51 (12) 12.91 (2.89-57.74)
Breslow
Continuous 248 (47) 1.07 (1.03-1.11) 248 (28) 1.08 (1.03-1.13)
Subtype
SSM, LMM, Other 195 (22) 1,00 195 (11) 1,00 1.00
Nodular 53 (24) 5.63 (3.15-10.08) 53 (16) 7.19 (3.32-15.57) 5.51 (2.39-12.71)
Ulceration
No 214 (30) 1,00 214 (18) 1,00
Yes 35 (16) 5.81 (3.13-10.80) 35 (9) 5.73 (2.59-12.97)
Lymphocytic
infiltrate
0-1 72 (20) 1,00 72 (11) 1,00
2-3 176 (26) 0.43 (0.24-0.78) 176 (16) 0.50 (0.23-1.08)
Clinical stage
I 179 (12) 1,00 1,00 179 (7) 1,00
II-IV 28 (13) 15.02 (6.39-35.30) 12.03 (4.49-32.28) 28 (8) 14.09 (4.82-41.18)
Mitotic count
<1/mm2 131 (7) 1,00 131 (3) 1,00
> = 1/mm2 122 (40) 7.96 (3.56-17.80) 122 (25) 11.25 (3.39-37.36)
Vascular invasion
No 232 (35) 1,00 1,00 232 (18) 1,00 1.00
Yes 14 (11) 9.25 (1.67-7.60) 3.56 (2.35-10.92) 14 (9) 11.29 (5.05-25.25) 8.26 (3.30-20.67)
Ki67 expression
Low (<=25 %) 159 (28) 1,00 159 (16) 1,00
High (>25 %) 47 (16) 2.46 (1.33-4.56) 47 (10) 2.64 (1.20-5.83)
RBM3 expression
Low 95 (24) 1.00 95 (17) 1.00 1.00
High 120 (20) 0.50 (0.27-0.91) 120(9) 0.29 (0.13-0.66) 0.30 (0.14-0.71)
MCM3 expression
Low (N ≤ S3) 133 (11) 1.00 1.00 133 (6) 1.00 1.00
High (NS > 3) 91 (34) 5.62 (2.83-11.13) 5.01 (0.33-10.79) 91 (21) 6.03 (2.42-15.02) 4.96 (1.77-13.87)

Low RBM3 expression corresponds to a nuclear staining intensity of negative to moderate and high expression corresponds to strong staining as previously described [12]. The number of cases in the multivariable analysis is equal to the number of cases evaluated for MCM3 expression (n = 224).

Nodin et al.

Nodin et al. Diagnostic Pathology 2012 7:82   doi:10.1186/1746-1596-7-82

Open Data